Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
10.1016/s0305-4179(01)00055-9 78 MiyamotoS.TakaokaK.OkadaT.YoshikawaH.HashimotoJ.SuzukiS.et al (1992)
doi:10.1186/gb-2002-3-3-reviews3004
doi:10.1039/c8bm01120f
The vast majority of studies included in the review focused on comparing DHP calcium channel blockers with hypotensive drugs from other groups (e.g., angiotensin-converting-enzyme inhibitors [ACE-Is], angiotensin receptor blockers [ARBs], mineralocorticoid receptor antagonist [MRAs], thiazide diuretics), various substances in the DHP calcium channel blocker group, or using them in combination
The peptides ability to produce metabolic effects with such rapid plasma clearance (3-minute half-life) while maintaining prolonged biological activity represents a significant knowledge gap requiring further investigation
